Doctors told to DOUBLE the dose of antibiotics gonorrhoea patients are given 'because the STI is quickly becoming resistant to medicine'
- Patients should be given an injected 1g dose of ceftriaxone for gonorrhoea
- This is double the 500mg dose, which has been recommended since 2011
- And experts said a secondary drug should be dropped altogether
- The British Association for Sexual Health and HIV published its guidance today
Doctors need to double the dose of antibiotics they give to patients with gonorrhoea because it's becoming resistant to medicine, experts have warned.
The British Association for Sexual Health and HIV (BASHH) today issued new guidelines for treating the STI for the first time since 2011.
Its recommendations follow news released earlier this month that two women in the UK caught 'super gonorrhoea' - one of whom was the first to ever catch it in Britain.
BASHH urges doctors to stop using one of the routine antibiotics and to increase the dose of another in what it called 'a major change'.
The bacteria which cause the STI gonorrhoea (pictured - a 3D illustration of Neisseria gonorrhoeae) are rapidly evolving to be able to survive antibiotics, therefore doctors are being urged to take more drastic lines of treatment to keep the infection under control
The BASHH recommendations include upping the dose of ceftriaxone – the front-line medication – from 500mg to 1g given by injection.
The 1g is four times as high as the 250mg dose recommended by the World Health Organization.
And BASHH said doctors should stop giving patients azithromycin, which used to be combined with ceftriaxone as a first resort.
Resistance to azithromycin is becoming too high, BASHH said, with up to nine per cent of infections being too strong for the drug.
Share this article
BASHH's third recommendation suggests using another, more powerful antibiotic straight away if a patient's infection is likely to survive the initial treatment.
This drug - ciprofloxacin - has in the past been reserved for infections that the first line of treatment failed to cure.
In their report, BASHH experts wrote: 'The move to ceftriaxone monotherapy represents a major change from the 2011 guideline.
'There is a lack of high quality evidence regarding the best strategy to delay the emergence of resistance.
'A high level of vigilance [including the] follow up of patients and test of cure coupled with maintenance of strong surveillance is vital in order to monitor the impact of this approach.'
Gonorrhoea is one of the most high profile infections known to be fighting back against antibiotics.
Overuse of the medications and constantly evolving strains of bacteria mean once-effective treatments no longer work every time.
On January 9 this year, Public Health England revealed two women in the UK had been diagnosed with 'super gonorrhoea' and required hospital treatment to be cured.
The women are believed to have been only the second and third people from the country to have caught it, after a man contracted it from a woman in Thailand last year.
Gonorrhoea is very common and infects around 45,000 people per year in the UK and 820,000 in the US.
Typical symptoms include discharge from the penis or vagina, pain when urinating, swelling of the foreskin, bleeding in between periods and abdominal pain.
If left untreated gonorrhoea can cause life-threatening and permanent health problems including infertility, pelvic inflammatory disease and arthritis.
